Molecular Cytogenetics Market worth $1.43 billion in 2030 7.1% CAGR | MarketsandMarkets™
DELRAY BEACH, Fla., Oct. 14, 2025 /PRNewswire/ -- The global Molecular Cytogenetics Market , valued at US$0.97 billion in 2024, is forecasted to grow at a robust CAGR of 7.1%, reaching US$1.02 billion in 2025 and an impressive US$1.43 billion by 2030. The market is driven by the rising incidence and prevalence of cancer & genetic disorders, the growing use of advanced technologies, and the increased use of molecular cytogenetics in clinical pathology testing. Furthermore, emerging markets are expected to drive market growth in the years to come.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=148469224
Browse in-depth TOC on " Molecular Cytogenetics Market "
139 - Tables
45 - Figures
235 - Pages
By product & service, the molecular cytogenetics market is segmented into kits & reagents, instruments, consumables, and software & services. Kits & reagents are expected to record the fastest growth during the forecast period. This surge is driven by their significant role in research, diagnostics, and clinical applications. End users, including hospitals, diagnostic laboratories, and research institutes, are increasingly shifting toward comprehensive, standardized solutions that ensure accuracy, speed, and reproducibility in detecting cancer and genetic disorders.
The adoption of ready-to-use kits and specialized reagents significantly streamlines workflows by eliminating the time-intensive processes of sourcing and validating individual probes, reagents, and other components. Furthermore, the availability of a broad range of probes, fluorescent affinity reagents, and other specialized kits, supported by continuous product innovations from leading manufacturers, is fueling demand in the molecular cytogenetics market.
By technique, the molecular cytogenetics market is segmented into comparative genomic hybridization, fluorescence in situ hybridization, chromogenic in situ hybridization, and other techniques. The comparative genomic hybridization segment accounted for the largest share of the molecular cytogenetics market in 2024 and is expected to continue leading during the forecast period. The molecular cytogenetics market is driven by its growing use in diagnosing chromosomal abnormalities associated with developmental delays, congenital anomalies, autism spectrum disorders, and other genetic conditions.
By allowing direct analysis of copy number variations without cell culturing, comparative genomic hybridization streamlines workflows and delivers faster, more reliable results than traditional cytogenetic methods. The evolution of array comparative genomic hybridization has further advanced the field by enabling the simultaneous analysis of multiple genomic regions, thereby significantly enhancing the detection of unbalanced karyotypes. This high-resolution capability is impactful in oncology, where comparative genomic hybridization reveals consistent patterns of genetic aberrations that inform tumor biology and treatment decisions.
By geography, The Asia Pacific region is projected to experience the most rapid growth within the molecular cytogenetics market. This growth is driven by the rising incidence of cancer and genetic disorders, increasing population, and strong government initiatives to improve healthcare infrastructure. Additionally, domestic and international players are actively strengthening their presence through partnerships, collaborations, and expansions, with local companies increasingly extending their global reach to capitalize on emerging opportunities across the region.
Request Sample Pages : https://www.marketsandmarkets.com/requestsampleNew.asp?id=148469224
Key players in the molecular cytogenetics market include Thermo Fisher Scientific Inc. (US), Illumina, Inc. (US), Danaher (US), F. Hoffmann-La Roche Ltd. (Switzerland), Revvity (US), Abbott (US), Agilent Technologies, Inc. (US), PacBio (US), Bio-Rad Laboratories, Inc. (US), and Bio-Techne (US), among others.
Danaher (US)
In 2024, SomnoMed ranked among the leading sleep apnea oral appliances market companies. The company has a strong distribution network in Europe and North America and is actively working on expanding its geographic presence along with its product portfolio. In recent years, SomnoMed has expanded its product portfolio to include innovative solutions. The firm's product launches are manufactured using ISO 13485 quality standards and FDA clearance.
Agilent Technologies, Inc. (US)
Agilent holds a notable position in the molecular cytogenetics market, offering a comprehensive portfolio of instruments, reagents, and software solutions for clinical and research applications. The company emphasizes high-precision cytogenetic analysis, integrating advanced imaging and genomic technologies to support cancer diagnostics and genetic research. In 2025, Agilent enhanced its market presence through strategic collaborations and product innovations that improve throughput, data accuracy, and workflow efficiency. With a strong focus on R&D and a global distribution network, Agilent ensures broad accessibility to its solutions, reinforcing its reputation for reliability and advancing its growth in the molecular cytogenetics sector.
Abbott (US)
Abbott strengthened its presence in the molecular cytogenetics market through innovative products and strategic partnerships. The company's offerings include automated cytogenetic analyzers, assays, and data management tools designed for precise chromosomal analysis in clinical and research settings. Abbott enables rapid, accurate, and reproducible results, particularly in oncology diagnostics and personalized medicine. In 2025, the company expanded its molecular cytogenetics capabilities through collaborations for integrating next-generation technologies into existing workflows. Abbott's commitment to global distribution, customer support, and continuous R&D, positions it as a competitive and trusted player in the evolving cytogenetics landscape.
For more information, Inquire Now!
Related Reports:
Monoclonal Antibody Therapeutics Market
Get access to the latest updates on Molecular Cytogenetics Companies and Molecular Cytogenetics Market Size
About MarketsandMarkets™:
MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.
Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.
The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.
To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter , LinkedIn and Facebook .
Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: [email protected]
Visit Our Website: https://www.marketsandmarkets.com/
Logo: https://mma.prnewswire.com/media/1868219/MarketsandMarkets_Logo.jpg
SOURCE MarketsandMarkets
Share this article